An analysis of new ADCs in Phase III studies shows the difficulties, and possible rewards, of developing these drugs. The earlier stage pipeline boasts a range of mechanistic approaches. 

With sales of its big sellers Jardiance and Ofev to start shrinking in the next few years, the German group is teeing up a suite of new drugs.

That is, if very early data in a handful of patients are borne out in later, larger studies.

Six biopharma companies have filed to list their shares on US exchanges so far this year, but the sums they are seeking are small.

An analysis of the most valuable research-stage products pinpoints several neurological candidates – and a deeper dive into this segment shows more CNS therapies that look to be worth big money.

Around 25 ADCs are in active Phase I/II trials, with a range of mechanistic approaches.